Loading clinical trials...
Loading clinical trials...
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Conditions
Interventions
Inclisiran
Evolocumab
Locations
52
United States
Novartis Investigative Site
Jacksonville, Florida, United States
Novartis Investigative Site
Indianapolis, Indiana, United States
Novartis Investigative Site
New York, New York, United States
Novartis Investigative Site
Cincinnati, Ohio, United States
Novartis Investigative Site
Cincinnati, Ohio, United States
Novartis Investigative Site
Greenville, Tennessee, United States
Start Date
April 27, 2017
Primary Completion Date
December 17, 2021
Completion Date
December 17, 2021
Last Updated
March 24, 2023
NCT07487363
NCT06813911
NCT06295679
NCT05277558
NCT06571162
NCT06541691
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions